Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Daltonics and Applied Biosystems License MALDI-TOF Mass Spectrometry Technology

NEW YORK, June 7 – Bruker Daltonics will exclusively license MALDI-TOF mass spectrometry technology from Indiana University, and grant Applied Biosystems a sublicense to the technology, the companies said Thursday. 

The patented technology covers space-velocity correlation focusing (SVCF), or delayed extraction (DE), a technique related to MALDI-TOF mass spectrometry. SVCF technology improves the accuracy and sensitivity mass spectrometry analysis, according to the companies.  

Bruker Daltonics is licensing the technology from Indiana University’s Advanced Research and Technology Institute, the technology-transfer arm of the university. Applied Biosystems will pay Bruker multi-year royalty payments for its sublicense to the technology. Bruker Daltonics and Applied Biosystems have cross-licensed each other’s technology related to SVCF.

“We believe that it is in the best interest of our customers in this field to jointly promote the MALDI-TOF market via a licensing program," said Frank Laukien, CEO of Bruker Daltonics, and Michael Hunkapiller, president of Applied Biosystems, in a statement.  
The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.